262
Participants
Start Date
February 23, 2009
Primary Completion Date
June 27, 2012
Study Completion Date
June 27, 2012
Riociguat (Adempas, BAY63-2521)
BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
Placebo
Matching Placebo tid orally for 16 weeks
Taipei
Bruxelles - Brussel
Vienna
Leuven
Prahran
Corrientes
Innsbruck
Zurich
Aarhus N
Vseobecna fakultni nemocnice, Prague
Caen
Mexico City
Greifswald
Hamburg
Baltimore
Pavia
Madrid
Hanover
Miami
Pessac
Istanbul
Izmir
Giessen
Querétaro
Columbus
Cleveland
Cologne
Iowa City
Lille
Monterrey
Monterrey
Homburg
Heidelberg
Heidelberg
Dallas
Rouen
München
La Jolla
Hopital Antoine Beclere, Clamart
Sacramento
Würzburg
Beijing
Beijing
Beijing
Saint Petersburg
Shanghai
Qingdao
Novosibirsk
Boston
Porto Alegre
São Paulo
Rio de Janeiro
Calgary
London
Ottawa
Toronto
Montreal
Brest
Nice
Vandœuvre-lès-Nancy
Dresden
Leipzig
Nagoya
Seto
Kitakyushu
Komatsu
Fujisawa
Kawasaki
Sendai
Suwa
Suita
Bunkyo-ku
Mitaka
Shinjuku-ku
Shinjuku-ku
Chiba
Fukuoka
Amsterdam
Krakow
Otwock
Coimbra
Bratislava
Seoul
Seoul
Barcelona
Ankara
Cambridge
Glasgow
London
Lead Sponsor
Bayer
INDUSTRY